中文

English

尊龙凯时生物医疗研究Blisibimod抗体蛋白

发布时间:2025-03-03   信息来源:尊龙凯时官方编辑

尊龙凯时 Research Grade Blisibimod (DHJ85305) 蛋白抗体

尊龙凯时生物医疗研究Blisibimod抗体蛋白

一、产品概述

中文名称:Research Grade Blisibimod,科研级贝利西单抗,精品蛋白抗体试剂盒。

二、产品描述

Blisibimod (A623) 是一种有效且选择性的四价 B 细胞激活因子(BAFF)抑制剂,广泛用于系统性红斑狼疮(SLE)的研究。

三、产品详情

名称: Research Grade Blisibimod,科研级贝利西单抗,体内中和抗体,活性抗体
货号: DHJ85305
表达系统: 哺乳动物细胞
种属反应性: 人类
宿主: 人类
同种型: Fusion-[peptide 16-mer-peptide 19-mer]2-IGHG1Fc (Fragment constant)
靶标: BAFF, ZTNF4, BLYS, 肿瘤坏死因子配体超级家族成员13B, 树突状细胞衍生的 TNF 类分子, TALL-1, TNF 和 APOL 相关白细胞表达配体 1, BLyS, B淋巴细胞刺激因子, TNFSF13B, CD257, TNFSF20, TALL1, B细胞激活因子
浓度: 0.5 mg/ml
内毒素水平: 请联系实验室了解更多信息
纯度: 通过 SDS-PAGE 确定为 95%
纯化方式: 从细胞培养上清液中通过 Protein A/G 纯化
Accession 号: Q9Y275
克隆号: Blisibimod
应用: Research Grade Biosimilar
状态: 液体
保存溶液: 0.01M PBS, pH 7.4
稳定性和存储: 使用手动霜冻冷冻库,避免重复冻融循环。短期存放于 4°C(1-2 周),长期存放于 -20°C(12 个月)或 -80°C(长期)。
别名: A-623

四、参考文献

1. Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser PMID: 27051973
2. Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date PMID: 28331294
3. A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP) PMID: 37755547
4. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity PMID: 23684423
5. Advances in natural products and antibody drugs for SLE: new therapeutic ideas PMID: 37492083
6. Emerging B-Cell Therapies in Systemic Lupus Erythematosus PMID: 33488082
7. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial PMID: 29563108
8. Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG623/A-623): results from randomized, double-blind phase 1a and phase 1b trials PMID: 26290435
9. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study PMID: 24748629
10. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus PMID: 24521424

如需更多信息,请咨询尊龙凯时 中国授权总代理 - 武汉佰乐博生物技术有限公司。作为法国 Antibodysystem 品牌在亚洲区的授权总代理,我们提供近三万种蛋白、抗体等生命科学核心试剂,旨在为科研工作者提供专业、全面、可靠的试剂产品。

免费热线:027-65279366 / 18108604356